Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CNTX Context Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: CNTX
Price (delayed)
$0.7708
Market cap
$69.14M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.31
Enterprise value
-$20.01M
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a
Highlights
CNTX's EPS has surged by 77% year-on-year and by 33% since the previous quarter
The quick ratio rose by 37% QoQ
Context Therapeutics's net income has decreased by 30% YoY and by 3.4% from the previous quarter
The equity is down by 4.5% since the previous quarter
Key stats
What are the main financial stats of CNTX
Market
Valuations
Earnings
Shares outstanding
89.7M
Market cap
$69.14M
Enterprise value
-$20.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.76
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$31.64M
Net income
-$27.63M
EBIT
-$27.63M
EBITDA
-$27.55M
Free cash flow
-$15.26M
Per share
Balance sheet
Liquidity
EPS
-$0.31
EPS diluted
-$0.31
Free cash flow per share
-$0.16
Book value per share
$1.01
Revenue per share
$0
TBVPS
$0.98
Total assets
$92.97M
Total liabilities
$1.98M
Debt
$193,706
Equity
$90.98M
Working capital
$90.83M
Debt to equity
0
Current ratio
48.8
Quick ratio
47.02
Net debt/EBITDA
3.24
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-29.1%
Return on equity
-29.8%
Return on invested capital
-5,306.7%
Return on capital employed
-30.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CNTX stock price
How has the Context Therapeutics stock price performed over time
Intraday
-0.31%
1 week
-11.36%
1 month
15.04%
1 year
-57.88%
YTD
-26.59%
QTD
25.95%
Financial performance
How have Context Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$31.64M
Net income
-$27.63M
Gross margin
N/A
Net margin
N/A
CNTX's operating income is down by 42% year-on-year and by 6% since the previous quarter
Context Therapeutics's net income has decreased by 30% YoY and by 3.4% from the previous quarter
Price vs fundamentals
How does CNTX's price correlate with its fundamentals
Growth
What is Context Therapeutics's growth rate over time
Valuation
What is Context Therapeutics stock price valuation
P/E
N/A
P/B
0.76
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CNTX's EPS has surged by 77% year-on-year and by 33% since the previous quarter
CNTX's P/B is 37% lower than its last 4 quarters average of 1.2
The equity is down by 4.5% since the previous quarter
Efficiency
How efficient is Context Therapeutics business performance
CNTX's ROE has soared by 78% year-on-year and by 19% since the previous quarter
The ROA has soared by 73% YoY and by 19% QoQ
Dividends
What is CNTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CNTX.
Financial health
How did Context Therapeutics financials performed over time
The current ratio is up by 37% since the previous quarter
The quick ratio rose by 37% QoQ
CNTX's debt is 100% smaller than its equity
CNTX's debt is down by 12% since the previous quarter
The equity is down by 4.5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.